医学
奥沙利铂
外科肿瘤学
新辅助治疗
胃切除术
养生
内科学
外科
化疗
阶段(地层学)
腺癌
肿瘤科
癌症
结直肠癌
胃肠病学
存活率
乳腺癌
古生物学
生物
作者
Yoshitaka Honma,Yasuhide Yamada,Tetsuji Terazawa,Atsuo Takashima,Satoru Iwasa,Ken Kato,Tetsuya Hamaguchi,Yasuhiro Shimada,Masaki Ohashi,Shinji Morita,Takeo Fukagawa,Nozomu Machida,Hitoshi Katai
出处
期刊:Surgery Today
[Springer Science+Business Media]
日期:2015-11-13
卷期号:46 (9): 1076-1082
被引量:23
标识
DOI:10.1007/s00595-015-1276-2
摘要
In Japan, the administration of S-1 following D2 gastrectomy is a standard treatment for stage II/III gastric cancer (GC). However, the survival of stage IIIB/IIIC GC remains unsatisfactory. To improve this, we conducted a multicenter phase II study to evaluate the safety and efficacy of a neoadjuvant S-1 and oxaliplatin regimen (SOX) followed by surgery targeted at stage III GC. Oxaliplatin was administered intravenously (130 mg/m2) on day 1, and S-1 was administered orally (40 mg/m2, twice a day) for 14 days followed by a seven-day rest period. After three cycles of therapy, D2 gastrectomy was performed. A total of 14 patients were enrolled and completed the protocol treatment. Grade 3/4 toxicities included thrombocytopenia (21.4 %), anorexia (14.3 %), and diarrhea (7.1 %). Seven patients (50 %) underwent total gastrectomy, and seven patients underwent distal gastrectomy. Grade 3/4 surgical complications included pancreatic fistula (21.4 %) and lung infection (7.1 %). The pathological response rate was 85.7 %. Although our data are limited and preliminary, neoadjuvant SOX followed by surgery can be performed safely with a high pathological response rate in patients with resectable advanced GC. Further investigation of this neoadjuvant approach is warranted.
科研通智能强力驱动
Strongly Powered by AbleSci AI